$PET
Wag! Group Co. Stock $pet

$pet Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000184235623000025 Filed on August 09, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2022 Q2
Revenue	$21.80M	$19.82M	$0.00
YoY Change	41.75%
Cost Of Revenue	$1.440M	$3.303M	$2.024M
YoY Change	-62.86%	63.19%
Gross Profit	$20.36M	$16.52M	$20.43M
YoY Change	77.01%	-19.14%
Gross Profit Margin	93.39%	83.34%
Selling, General & Admin	$17.44M	$15.58M	$1.570M
YoY Change	-50.28%	892.61%	9789.73%
% of Gross Profit	85.64%	94.32%	7.68%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$414.0K	$375.0K	$297.0K
YoY Change	208.96%	26.26%
% of Gross Profit	2.03%	2.27%	1.45%
Operating Expenses	$17.44M	$15.58M	$1.570M
YoY Change	-50.28%	892.61%	9789.73%
Operating Profit	$2.923M	$938.0K	-$1.570M
YoY Change	-112.4%	-159.76%	36925.27%
Interest Expense	$1.683M	$1.659M	$177.5K
YoY Change	-328.98%	834.44%
% of Operating Profit	57.58%	176.87%
Other Income/Expense, Net	-$10.00K	-$65.00K	$177.5K
YoY Change	-99.93%	-136.61%
Pretax Income	-$2.155M	-$4.384M	-$1.392M
YoY Change	-94.74%	214.95%	8671.01%
Income Tax	$41.00K	$38.00K	$13.00K
% Of Pretax Income
Net Earnings	-$2.196M	-$3.869M	-$1.392M
YoY Change	-94.63%	177.95%	32737.08%
Net Earnings / Revenue	-10.07%	-19.52%
Basic Earnings Per Share	-$0.06	-$0.10	-$0.18
Diluted Earnings Per Share	-$0.06	-$0.10	-$88.73K
COMMON SHARES
Basic Shares Outstanding	38.78M shares	37.49M shares	15.69M
Diluted Shares Outstanding	38.99M shares	38.11M shares	6.129M shares

Balance Sheet

Concept	2023 Q3	2023 Q2	2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$22.30M	$24.80M	$168.3K
YoY Change	-20.43%	14639.97%	736.65%
Cash & Equivalents	$22.30M	$24.79M	$168.2K
Short-Term Investments
Other Short-Term Assets	$3.500M	$2.000M	$317.3K
YoY Change	-87.62%	530.42%
Inventory
Prepaid Expenses
Receivables	$8.485M	$7.762M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$34.29M	$34.54M	$554.1K
YoY Change	-45.26%	6133.28%	2655.3%
LONG-TERM ASSETS
Property, Plant & Equipment	$71.00K	$89.00K
YoY Change	5.97%
Goodwill	$4.600M	$5.096M
YoY Change	222.35%
Intangibles	$8.036M	$7.814M
YoY Change	219.27%
Long-Term Investments			$125.2M
YoY Change
Other Assets	$63.00K	$2.092M	$48.05K
YoY Change	-19.23%	4253.8%	-73.41%
Total Long-Term Assets	$13.94M	$16.30M	$125.2M
YoY Change	220.2%	-86.98%	69215.24%
TOTAL ASSETS
Total Short-Term Assets	$34.29M	$34.54M	$554.1K
Total Long-Term Assets	$13.94M	$16.30M	$125.2M
Total Assets	$48.22M	$50.84M	$125.8M
YoY Change	-28.01%	-59.59%	62548.97%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.686M	$9.672M	$81.51K
YoY Change	75.09%	11765.59%	1864.17%
Accrued Expenses	$4.404M	$4.150M	$3.621M
YoY Change	-20.73%	14.6%	6457.99%
Deferred Revenue	$1.768M	$2.627M
YoY Change	-19.12%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due	$1.589M	$1.427M
YoY Change	35.93%
Total Short-Term Liabilities	$17.47M	$18.88M	$3.703M
YoY Change	-49.51%	409.85%	1831.98%
LONG-TERM LIABILITIES
Long-Term Debt	$25.71M	$25.57M	$0.00
YoY Change	4.96%
Other Long-Term Liabilities	$218.0K	$218.0K	$4.375M
YoY Change	-66.51%	-95.02%
Total Long-Term Liabilities	$25.93M	$25.79M	$4.375M
YoY Change	5.85%	489.44%
TOTAL LIABILITIES
Total Short-Term Liabilities	$17.47M	$18.88M	$3.703M
Total Long-Term Liabilities	$25.93M	$25.79M	$4.375M
Total Liabilities	$44.30M	$45.80M	$8.078M
YoY Change	-25.86%	466.92%	4114.67%
SHAREHOLDERS EQUITY
Retained Earnings	-$158.3M	-$156.1M	-$7.476M
YoY Change	2.64%	1988.01%
Common Stock	$4.000K	$4.000K	$318.00
YoY Change	0.0%	1157.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.923M	$5.044M	-$7.476M
YoY Change
Total Liabilities & Shareholders Equity	$48.22M	$50.84M	$125.8M
YoY Change	-28.01%	-59.59%	62548.97%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2022 Q2
OPERATING ACTIVITIES
Net Income	-$2.196M	-$3.869M	-$1.392M
YoY Change	-94.63%	177.95%	32737.08%
Depreciation, Depletion And Amortization	$414.0K	$375.0K	$297.0K
YoY Change	208.96%	26.26%
Cash From Operating Activities	-$2.290M	$1.253M	-$166.9K
YoY Change	-25.13%	-850.7%	1322.93%
INVESTING ACTIVITIES
Capital Expenditures	$10.00K	$15.00K
YoY Change	-72.22%
Acquisitions
YoY Change
Other Investing Activities	$740.0K	-$710.0K
YoY Change	-62.78%
Cash From Investing Activities	$730.0K	-$725.0K
YoY Change	-62.6%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-920.0K	-238.0K	0.000
YoY Change	-101.79%		-100.0%
NET CHANGE
Cash From Operating Activities	-2.290M	1.253M	-166.9K
Cash From Investing Activities	730.0K	-725.0K
Cash From Financing Activities	-920.0K	-238.0K	0.000
Net Change In Cash	-2.480M	290.0K	-166.9K
YoY Change	-104.92%	-273.75%	-929.99%
FREE CASH FLOW
Cash From Operating Activities	-$2.290M	$1.253M	-$166.9K
Capital Expenditures	$10.00K	$15.00K
Free Cash Flow	-$2.300M	$1.238M
YoY Change	-25.68%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q2	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	300000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	1000000	usd
CY2023Q2	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-65000	usd
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	0	usd
CY2023Q2	us-gaap	Interest Expense InterestExpense	1659000	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	17000	usd
	us-gaap	Interest Expense InterestExpense	3289000	usd
	us-gaap	Interest Expense InterestExpense	49000	usd
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.18
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.20
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.20
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37590000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37590000	shares
CY2022Q1	pet	Temporary Equity Stock Issued During Period Shares New Issues TemporaryEquityStockIssuedDuringPeriodSharesNewIssues	1100000	shares
CY2022Q1	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues	11000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-2350000	usd
CY2022Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	24959000	shares
CY2022Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	121000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-108409000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	40000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-1090000	usd
CY2022Q2	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	24959000	shares
CY2022Q2	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	121000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-109459000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7656000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3440000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2463000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	94000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1314000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	756000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	297000	usd
	us-gaap	Paid In Kind Interest PaidInKindInterest	36000	usd
	us-gaap	Paid In Kind Interest PaidInKindInterest	58000	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	553000	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1850000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1854000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1049000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	59000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	14000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	5000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	0	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2241000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1060000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-700000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-536000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	368000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	220000	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	218000	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	0	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2327000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4146000	usd
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	0	usd
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	10092000	usd
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	0	usd
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	5901000	usd
	us-gaap	Payment For Contingent Consideration Liability Investing Activities PaymentForContingentConsiderationLiabilityInvestingActivities	382000	usd
	us-gaap	Payment For Contingent Consideration Liability Investing Activities PaymentForContingentConsiderationLiabilityInvestingActivities	375000	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	9503000	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	usd
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	1470000	usd
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	0	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	31000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	14000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-11386000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4580000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	90000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	551000	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	220000	usd
	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	0	usd
	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	10925000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	2169000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-461000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8536000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-14174000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-190000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	38966000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2628000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	24792000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2438000	usd
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2023Q2	pet	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	0.97
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:18pt;padding-left:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgments, and assumptions that affect the reported amounts of assets and liabilities and disclosures as of the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates on various factors, including historical experience, and on various other assumptions that are believed to be reasonable under the circumstances, when these carrying values are not readily available from other sources.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant items subject to estimates and assumptions include, but are not limited to, fair values of financial instruments, assumptions used in the valuation of common and preferred stock, valuation of stock-based compensation and warrants, and the valuation allowance for deferred income taxes. Actual results may differ from these estimates.</span></div>
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-156100000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-148400000	usd
CY2022Q4	us-gaap	Payments To Acquire Interest In Subsidiaries And Affiliates PaymentsToAcquireInterestInSubsidiariesAndAffiliates	1500000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	Cash, cash equivalents, investments, and amounts at payment processors are potentially subject to concentration of credit risk. Such balances are maintained at financial institutions that management determines to be of high-credit quality. Cash accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to certain limits. At times, such deposits may be in excess of the FDIC insurance limit. The Company has not experienced any losses on its deposits.
CY2023Q2	us-gaap	Advertising Expense AdvertisingExpense	1600000	usd
CY2022Q2	us-gaap	Advertising Expense AdvertisingExpense	1600000	usd
	us-gaap	Advertising Expense AdvertisingExpense	3700000	usd
	us-gaap	Advertising Expense AdvertisingExpense	3500000	usd
CY2022Q3	pet	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	0.97
CY2022Q3	pet	Proceeds From Redemption Of Common Stock ProceedsFromRedemptionOfCommonStock	29100000	usd
CY2022Q3	pet	Proceeds From Redemption Of Common Stock Classified As Restricted Cash Current ProceedsFromRedemptionOfCommonStockClassifiedAsRestrictedCashCurrent	23900000	usd
CY2022Q3	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	5000000	usd
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	91130	shares
CY2022Q3	pet	Number Of Lenders NumberOfLenders	2	lender
CY2022Q3	pet	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	0.97
CY2022Q3	pet	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	0.97
CY2022Q3	pet	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	0.97
CY2022Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	24700000	usd
CY2022Q3	pet	Derivative Instrument Contingent Consideration Liability Shares DerivativeInstrumentContingentConsiderationLiabilityShares	2393378	shares
CY2022Q3	pet	Derivative Instrument Contingent Consideration Liability Price Per Share DerivativeInstrumentContingentConsiderationLiabilityPricePerShare	10.30
CY2022Q4	pet	Derivative Instrument Contingent Consideration Liability Holders Repurchasing Shares DerivativeInstrumentContingentConsiderationLiabilityHoldersRepurchasingShares	1400000	holder
CY2022Q4	pet	Derivative Instrument Contingent Consideration Liability Repurchase Price DerivativeInstrumentContingentConsiderationLiabilityRepurchasePrice	14800000	usd
CY2022Q4	pet	Derivative Instrument Contingent Consideration Liability Shares DerivativeInstrumentContingentConsiderationLiabilityShares	955000	shares
CY2022Q4	pet	Derivative Instrument Contingent Consideration Liability Proceeds From Release Of Restricted Cash DerivativeInstrumentContingentConsiderationLiabilityProceedsFromReleaseOfRestrictedCash	9800000	usd
CY2022Q3	pet	Cash Acquired Through Reverse Recapitalization CashAcquiredThroughReverseRecapitalization	28330000	usd
CY2022Q3	pet	Payments Of Reverse Recapitalization Transaction Costs PaymentsOfReverseRecapitalizationTransactionCosts	12488000	usd
CY2022Q3	pet	Reverse Recapitalization Accrued Transaction Costs ReverseRecapitalizationAccruedTransactionCosts	9318000	usd
CY2022Q3	pet	Reverse Recapitalization Net ReverseRecapitalizationNet	11726000	usd
CY2022Q3	pet	Reverse Recapitalization Reversal Of Additional Paid In Capital Impact Recorded Upon Issuance Of Forward Purchase Agreements ReverseRecapitalizationReversalOfAdditionalPaidInCapitalImpactRecordedUponIssuanceOfForwardPurchaseAgreements	23203000	usd
CY2022Q4	pet	Derivative Instrument Contingent Consideration Liability Proceeds From Release Of Restricted Cash DerivativeInstrumentContingentConsiderationLiabilityProceedsFromReleaseOfRestrictedCash	9837000	usd
CY2022Q4	pet	Reverse Recapitalization Additional Paid In Capital Impact Of Forward Purchase Agreement Net Of Cash Received ReverseRecapitalizationAdditionalPaidInCapitalImpactOfForwardPurchaseAgreementNetOfCashReceived	4229000	usd
CY2022Q4	pet	Reverse Recapitalization Net ReverseRecapitalizationNet	2589000	usd
CY2022Q3	pet	Stock Issued During Period Shares Reverse Recapitalization StockIssuedDuringPeriodSharesReverseRecapitalization	6524000	shares
CY2022Q3	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	122000	shares
CY2022Q3	pet	Stock Issued During Period Shares Reverse Recapitalization And Other StockIssuedDuringPeriodSharesReverseRecapitalizationAndOther	6646000	shares
CY2022Q3	pet	Stock Converted Reverse Recapitalization StockConvertedReverseRecapitalization	31100000	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37746000	shares
CY2022Q3	pet	Derivative Instrument Contingent Consideration Liability Shares DerivativeInstrumentContingentConsiderationLiabilityShares	2393378	shares
CY2022Q3	us-gaap	Shares Outstanding SharesOutstanding	30863283	shares
CY2022Q4	pet	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	0.97
CY2022Q3	pet	Reverse Recapitalization Contingent Consideration Equity Earnout Period ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriod	P3Y
CY2022Q3	pet	Stock Issued During Period Value Reverse Recapitalization Contingent Consideration Equity StockIssuedDuringPeriodValueReverseRecapitalizationContingentConsiderationEquity	23900000	usd
CY2023Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2600000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2200000	usd
CY2023Q2	pet	Reverse Recapitalization Transaction Costs ReverseRecapitalizationTransactionCosts	39500000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	19820000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12784000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	40443000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	22450000	usd
CY2023Q2	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	600000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	500000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P30M
CY2022Q4	pet	Lessee Future Operating Lease Monthly Base Rent LesseeFutureOperatingLeaseMonthlyBaseRent	20400	usd
CY2022Q4	pet	Lessee Future Operating Lease Monthly Rent Increase Percent LesseeFutureOperatingLeaseMonthlyRentIncreasePercent	0.030
CY2022Q4	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P13M
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	79000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	414000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	424000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	216000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	175000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	163000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1471000	usd
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y10M24D
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.079
CY2023Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	713000	usd
CY2023Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	1751000	usd
CY2023Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	30227000	usd
CY2023Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	32691000	usd
CY2022Q3	pet	Line Of Credit Facility Financial Covenants Minimum Liquidity LineOfCreditFacilityFinancialCovenantsMinimumLiquidity	5000000	usd
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q2	pet	Common Stock Exchange Ratio CommonStockExchangeRatio	0.97
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y2M8D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	19292000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y8M1D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	11000000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1121000	usd
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	40000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2463000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	94000	usd
CY2022Q3	pet	Number Of Lenders NumberOfLenders	2
CY2021Q3	pet	Fair Value Of Warrants Price FairValueOfWarrantsPrice	1.32
CY2023Q2	pet	Class Of Warrant Or Right Redemption Of Warrants Or Rights Reference Price ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsReferencePrice	16.50
	pet	Class Of Warrant Or Right Redemption Of Warrants Or Rights Threshold Trading Days ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays	20	day
	pet	Class Of Warrant Or Right Redemption Of Warrants Or Rights Consecutive Trading Days ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsConsecutiveTradingDays	30	day
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	38000	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	13000	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	42841000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	32547000	shares

Files In Submission

Name	View Source	Status
0001842356-23-000025-index-headers.html	Edgar Link	pending
0001842356-23-000025-index.html	Edgar Link	pending
0001842356-23-000025.txt	Edgar Link	pending
0001842356-23-000025-xbrl.zip	Edgar Link	pending
exhibit311q22023.htm	Edgar Link	pending
exhibit312q22023.htm	Edgar Link	pending
exhibit321q22023.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pet-20230630.htm	Edgar Link	pending
pet-20230630.xsd	Edgar Link	pending
pet-20230630_g1.jpg	Edgar Link	pending
pet-20230630_g2.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
pet-20230630_def.xml	Edgar Link	unprocessable
pet-20230630_pre.xml	Edgar Link	unprocessable
pet-20230630_htm.xml	Edgar Link	completed
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
pet-20230630_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
pet-20230630_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PET
Wag! Group Co. Stock $pet

2023 Q3 Form 10-Q Financial Statement

#000184235623000025 Filed on August 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PET Wag! Group Co. Stock $pet

2023 Q3 Form 10-Q Financial Statement

#000184235623000025 Filed on August 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PET
Wag! Group Co. Stock $pet